Scott C. Woller, MD

Research Interests

  • Venous Thrombosis
  • Antithrombotic Therapy

Languages

  • English
  • Portuguese
  • Spanish

Academic Information

  • Departments: Internal Medicine - Professor (Clinical)
  • Divisions: General Internal Medicine

Board Certification

  • American Board of Internal Medicine (Internal Medicine)

Academic Bio

Dr. Woller’s academic interests reside in thrombosis medicine and anticoagulation management. With a particular interest in the prevention of venous thromboembolic disease, Dr. Woller has served as investigator on multiple ongoing and completed clinical trials including the NIH-funded studies (COAG, GIFT) serving as site PI for GIFT. Dr. Woller is Co-Chair for the American College of Chest Physicians (ACCP) Clinical Practice Guideline that addresses antithrombotic therapy for venous thromboembolic disease, and as was a panelist for the Vascular Access Appropriateness Panel housed at the University of Michigan. Dr. Woller is an invited panelist for the Centers for Disease Control and Prevention (CDC) Risk Assessment Model for the Prevention of Venous Thromboembolic Disease in Medical Patients program.

Dr. Woller is Professor of Medicine, University of Utah School of Medicine, Professor in Research, Intermountain Healthcare, and is a recognized teacher and recipient of the Intermountain Medical Center Housestaff Teaching Award (2011), the University of Utah School of Medicine Outstanding Faculty Teaching Award (2012), and the University of Utah Department of Internal Medicine Outstanding Faculty Subspecialty Teaching Award (2021). Dr. Woller, Fellow of the American College of Chest Physicians (FCCP) and Fellow of the American College of Physicians (FACP), is Utah Chapter Governor of the American College of Physicians (Class of 2025). Dr. Woller's research group was awarded the 2015 U.S. Centers for Disease Control and Prevention (CDC) Healthcare-Associated Venous Thromboembolism (HA-VTE) Prevention Challenge Award.

Dr. Woller received his medical degree from Northwestern University Medical School in 2000. Dr. Woller completed his residency at the University of Utah Hospital (2003) then served as Chief Medical Resident in 2003-04. Dr. Woller is Board Certified in Internal Medicine and attends at the Intermountain Medical Center, Murray UT where he serves as Chair of Medicine.

Education History

Type School Degree
Chief Resident University of Utah School of Medicine
Internal Medicine
Chief Resident
Residency University of Utah School of Medicine
Internal Medicine
Resident
Internship University of Utah School of Medicine
Internal Medicine
Intern
Professional Medical Northwestern University Medical School
Medicine
M.D.
Undergraduate University of Wisconsin - Milwaukee
Biological Sciences
B.S.

Global Impact

Presentations

Description Country
Treatment of venous thromboembolism in Special Populations. Mexican College of Internal Medicine 53rd Annual National Congress & Global International Summit of Internal Medicine. Virtual Congress Argentina

Selected Publications

Journal Article

  1. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK (2021). Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest, 160(6), e545-e608.
  2. Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK (2021). Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest, 160(6), 2247-2259.
  3. Woller SC, Stevens SM, Kaplan D, Wang TF, Branch DW, Groat D, Wilson EL, Armbruster B, Aston VT, Lloyd JF, Rondina MT, Elliott CG (2021). Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv.
  4. Rizzi SA, Knight S, May HT, Woller SC, Stevens SM, Steinberg BA, Bair TL, Anderson JL, Muhlestein JB, Knowlton KU, Bunch TJ (2021). Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. Am J Cardiol, 153, 58-64.
  5. Woller SC, Stevens SM, Fazili M, Lloyd JF, Wilson EL, Snow GL, Bledsoe JR, Horne BD (2021). Post-discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers. Res Pract Thromb Haemost, 5(5), e12560.
  6. Bledsoe JR, Kelly C, Stevens SM, Woller SC, Haug P, Lloyd JF, Allen TL, Butler AM, Jacobs JR, Elliott CG (2021). Electronic pulmonary embolism clinical decision support and effect on yield of computerized tomographic pulmonary angiography: ePE-A pragmatic prospective cohort study. J Am Coll Emerg Physicians Open, 2(4), e12488.
  7. Kay AB, Morris DS, Woller SC, Stevens SM, Bledsoe JR, Lloyd JF, Collingridge DS, Majercik S (2021). Trauma patients at risk for venous thromboembolism who undergo routine duplex ultrasound screening experience fewer pulmonary emboli: A prospective randomized trial. J Trauma Acute Care Surg, 90(5), 787-796.
  8. Bledsoe JR, Woller SC, Stevens SM, Aston V, Patten R, Allen T, Horne BD, Dong L, Lloyd J, Snow G, Madsen T, Fink P, Elliott CG (2020). Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study. Am J Emerg Med, 41, 80-83.
  9. Woller B, Daw A, Aston V, Lloyd J, Snow G, Stevens SM, Woller SC, Jones P, Bledsoe J (2021). Natural Language Processing Performance for the Identification of Venous Thromboembolism in an Integrated Healthcare System. Clin Appl Thromb Hemost, 27, 10760296211013108.
  10. Barbhaiya, Medha Zuily, Stephane Ahmadzadeh, Yasaman Amigo, MaryCarmen Avcin, Tadej Bertolaccini, Maria Laura Branch, D Ware de Jesus, Guilherme Devreese, Katrien MJ Frances, Camille Garcia, David Guillemin, Francis Levine, Steven R Levy, Roger A Lockshin, Michael D Ortel, Thomas L Seshan, Surya V Tektonidou, Maria Wahl, Denis Willis, Rohan Naden, Ray Costenbader, Karen Erkan, Doruk New APS Classification Criteria Collaborators AgmonLevin, Nancy Aguilar, Cassyanne Alba, Paula Alpan, Oral Ambrozic, Ales Amoura, Zahir Andrade, Danieli Andrade, Luis Appenzeller, Simone Artim Esen, Bahar Atsumi, Tatsuya Berkun, Yackov Cabral, Antonio Canaud, Guillaume Cervera, Ricard Chen, Pojen Chighizola, Cecilia Cimaz, Rolando Cohen, Hannah CostedoatChalumeau, Nathalie Crowther, Mark Jose Cuadrado, Maria de Groot, Philip G de Moerloose, Philippe De Sancho, Maria Derksen, Ronald DizKucukkaya, Reyhan Drner, Thomas Fortin, Paul GomezPuerto, Jose (2020). Development of New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care Res, doi:10.1002/acr.24520.
  11. Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Williams DJ, Willis R, Woller SC, Andrade D (2020). 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus, 29(12), 1571-1593.
  12. Takada T, van Doorn S, Parpia S, de Wit K, Anderson DR, Stevens SM, Woller SC, Ten Cate-Hoek AJ, Elf JL, Kraaijenhagen RA, Schutgens REG, Wells PS, Kearon C, Moons KGM, Geersing GJ (2020). Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data meta-analysis. J Thromb Haemost, 18(9), 2245-2252.
  13. Zuily S, Cohen H, Isenberg D, Woller SC, Crowther M, Dufrost V, Wahl D, Dor CJ, Cuker A, Carrier M, Pengo V, Devreese KMJ (2020). Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost, 18(9), 2126-2137.
  14. Darzi AJ, Karam SG, Spencer FA, Spyropoulos AC, Mbuagbaw L, Woller SC, Zakai NA, Streiff MB, Gould MK, Cushman M, Charide R, Etxeandia-Ikobaltzeta I, Germini F, Rigoni M, Agarwal A, Morsi RZ, Akl EA, Iorio A, Schnemann HJ (2020). Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. Blood Adv, 4(12), 2557-2566.
  15. Snyder L, Stevens SM, Fazili M, Wilson EL, Lloyd JF, Horne BD, Bledsoe J, Woller SC (2020). Predicting postdischarge hospital-associated venous thromboembolism among medical patients using a validated mortality risk score derived from common biomarkers. Res Pract Thromb Haemost, 4(5), 872-878.
  16. Darzi AJ, Karam SG, Charide R, Etxeandia-Ikobaltzeta I, Cushman M, Gould MK, Mbuagbaw L, Spencer FA, Spyropoulos AC, Streiff MB, Woller S, Zakai NA, Germini F, Rigoni M, Agarwal A, Morsi RZ, Iorio A, Akl EA, Schnemann HJ (2019). Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood, 135(20), 1788-1810.
  17. Kelly C, Bledsoe JR, Woller SC, Stevens SM, Jacobs JR, Butler AM, Quinn J (2019). Diagnostic yield of pulmonary embolism testing in patients presenting to the emergency department with syncope. Res Pract Thromb Haemost, 4(2), 263-268.
  18. Fazili M, Stevens SM, Woller SC (2019). Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance. Res Pract Thromb Haemost, 4(1), 9-12.
  19. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Anderson JL, Li J, Rodriguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dvila-Romn V, Eby CS (2019). Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. JAMA, 322(9), 834-842.
  20. Woller SC, Stevens SM, Johnson SA, Bledsoe JR, Galovic B, Lloyd JF, Wilson EL, Armbruster B, Evans RS (2019). Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM-DVT): Methods of a prospective single-arm management study. Res Pract Thromb Haemost, 3(3), 340-348.
  21. Moyer GC, Bannow BS, Thornburg C, Rosovsky R, Wang TF, Woller S, Thornhill D, Kreuziger LB (2018). Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. Clin Appl Thromb Hemost, 24(9_suppl), 209S-216S.
  22. Willoughby L, Adams DM, Evans RS, Lloyd JF, Stevens SM, Woller SC, Bledsoe JR, Aston VT, Wilson EL, Elliott CG (2017). Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism: Are Guidelines Followed? Chest, 153(5), 1153-1159.
  23. Cox N, Johnson SA, Vazquez S, Fleming RP, Rondina MT, Kaplan D, Chauv S, Fontaine GV, Stevens SM, Woller S, Witt DM (2017). Patterns and Appropriateness of Thrombophilia Testing in an Academic Medical Center. J Hosp Med, 12(9), 705-709.
  24. Golive A, May HT, Bair TL, Jacobs V, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, Woller SC, Bunch TJ (2017). The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation. Am J Cardiol, 120(1), 75-82.
  25. Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, Woller SC, Bunch TJ (2016). Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. Am J Cardiol, 118(2), 210-4.
  26. Fontaine GV, Vigil E, Wohlt PD, Lloyd JF, Evans RS, Collingridge DS, Stevens SM, Woller SC (2016). Venous Thromboembolism in Critically Ill Medical Patients Receiving Chemoprophylaxis: A Focus on Obesity and Other Risk Factors. Clin Appl Thromb Hemost, 22(3), 265-73.
  27. Woller SC, Stevens SM, Evans RS (2016). The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) initiative: A summary and review of peripherally inserted central catheter and venous catheter appropriate use. J Hosp Med, 11(4), 306-10.
  28. Woller SC, Stevens SM, Kaplan DA, Branch DW, Aston VT, Wilson EL, Gallo HM, Johnson EG, Rondina MT, Lloyd JF, Evans RS, Elliott CG (2016). Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). Clin Appl Thromb Hemost, 22(3), 239-47.
  29. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L (2016). Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 149(2), 315-352.
  30. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, Lim W, Douketis JD (2016). Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis, 41(1), 154-64.
  31. Jacobs V, Woller SC, Stevens SM, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, Mallender C, Anderson JL, Bunch TJ (2015). Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of Dementia. J Cardiovasc Electrophysiol, 26(11), 1180-1186.
  32. Chopra V, Flanders SA, Saint S, Woller SC, OGrady NP, Safdar N, Trerotola SO, Saran R, Moureau N, Wiseman S, Pittiruti M, Akl EA, Lee AY, Courey A, Swaminathan L, LeDonne J, Becker C, Krein SL, Bernstein SJ, Michigan Appropriateness Guide for Intravenouse Catheters MAGIC Panel (2015). The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method. Ann Intern Med, 163(6 Suppl), S1-40.
  33. Greene MT, Flanders SA, Woller SC, Bernstein SJ, Chopra V (2015). The Association Between PICC Use and Venous Thromboembolism in Upper and Lower Extremities. Am J Med, 128(9), 986-93.e1.
  34. Stevens SM, Woller SC (2015). Ultrasound of the Whole Arm to Manage Suspected Upper-Extremity Deep Venous Thrombosis. JAMA Intern Med, 175(7), 1227-9.
  35. Woller SC, Stevens SM, Towner S, Olson J, Christensen P, Hamilton S, Newman L, Mott L, Hu P, Brunisholz KD, Long Y, Lloyd J, Evans RS, Cannon W, Elliott CG (2015). Computerized clinical decision support improves warfarin management and decreases recurrent venous thromboembolism. Clin Appl Thromb Hemost, 21(3), 197-203.
  36. Kearon C, Spencer FA, OKeeffe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaats S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA (2015). d-Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy: A Cohort Study. Ann Intern Med, 162(1), 27-34.
  37. Woller SC, Stevens SM, Adams DM, Evans RS, Lloyd JF, Snow GL, Bledsoe JR, Gay DZ, Patten RM, Aston VT, Elliott CG (2014). Assessment of the safety and efficiency of using an age-adjusted D-dimer threshold to exclude suspected pulmonary embolism. Chest, 146(6), 1444-1451.
  38. Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL, Crandall BG, Day JD, Johanning K, Long Y, Mallender C, Olson JL, Osborn JS, Weiss JP, Bunch TJ (2014). Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm, 11(12), 2206-13.
  39. Fontaine GV, Mathews KD, Woller SC, Stevens SM, Lloyd JF, Evans RS (2014). Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. Clin Appl Thromb Hemost, 20(7), 665-72.
  40. Geersing GJ, Zuithoff NP, Kearon C, Anderson DR, Ten Cate-Hoek AJ, Elf JL, Bates SM, Hoes AW, Kraaijenhagen RA, Oudega R, Schutgens RE, Stevens SM, Woller SC, Wells PS, Moons KG (2014). Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 348, g1340.
  41. Kimmel S, French B, Kasner S, Johnson J, Anderson J, Gage B, Rosenberg Y, Eby C, Madigan R, McBane R, Abdel-Rahman S, Stevens SM, Yale S, Mohler E, Fang M, Shay V, Horenstein R, Limdi N, Muldowney J, Gujral J, Delafontaine P, Desnick R, Ortel T, Billett H, Pendleton R, Geller N, Halperin J, Goldhaber S (11/19/2013). A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med, 369(24), 2283-93.
  42. Stevens SM, Woller SC (2013). Intermittent pneumatic compression in patients with stroke. Lancet, 382(9891), 484-6.
  43. Evans RS, Sharp JH, Linford LH, Lloyd JF, Woller SC, Stevens SM, Elliott CG, Tripp JS, Jones SS, Weaver LK (2013). Reduction of peripherally inserted central catheter-associated DVT. Chest, 143(3), 627-633.
  44. Stevens SM, Woller SC, Graves KK, Aston V, Jones J, Snow G, Elliott CG (2013). Withholding anticoagulation following a single negative whole-leg ultrasound in patients at high pretest probability for deep vein thrombosis. Clin Appl Thromb Hemost, 19(1), 79-85.
  45. Grant JD, Stevens SM, Woller SC, Lee EW, Kee ST, Liu DM, Lohan DG, Elliott CG (2012). Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thromb Haemost, 108(6), 1097-108.
  46. Sarma A, Heilbrun ME, Conner KE, Stevens SM, Woller SC, Elliott CG (2012). Radiation and chest CT scan examinations: what do we know? Chest, 142(3), 750-760.
  47. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP, Huntinghouse JA, Rollo JS, Siler D, Bair TL, Knight S, Muhlestein JB, Carlquist JF (2012). A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation, 125(16), 1997-2005.
  48. Woller SC, Bertin KC, Stevens SM, Hanseen RB, Hickman JM, Samuelson KM, Barton S, Lloyd JF, Evans RS, Jones JP, Elliott CG (2012). A Prospective Comparison of Warfarin to Aspirin for Thromboprophylaxis in Total Hip and Total Knee Arthroplasty. J Arthroplasty, 27(1), 1-9.
  49. Woller SC, Stevens SM, Jones JP, Lloyd JF, Evans RS, Aston VT, Elliott CG (2011). Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med, 124(10), 947-954.e2.

Review

  1. Sarma A, Heilbrun ME, Conner KE, Stevens SM, Woller SC, Elliott CG (2012). Radiation and Chest CT Examinations: What do we know? [Review]. Chest, 142(3), 750-760.

Editorial

  1. Stevens SM, Fazili M, Woller SC (2020). Choosing ultrasound technique for suspected deep vein thrombosis: which is best? Quant Imaging Med Surg, 10(6), 1418-1421.

Letter

  1. Schwab-Daugherty EM, Peng MR, Caraccio EE, Stevens SM, Woller SC (2020). Timing of parenteral anticoagulation after thrombolysis for the treatment of pulmonary embolism. [Letter to the editor]. Thromb Res, 195, 58-61.
  2. Woller SC, Stevens SM, Kaplan DA, T Rondina M (2017). Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome Study. [Letter to the editor]. Clin Appl Thromb Hemost, 24(1), 192.
  3. Woller SC, Stevens SM (2012). The reply. [Letter to the editor]. Am J Med, 125(11), e25-6.

Abstract

  1. Fidel Lopez-Verdugo F, LeCorchick S, Sanchez-Garcia J, Dow S, Krong J, Harmston G, Boschert ME, Zendejas I, Frech EJ, Gagnon AI, Jones R, Fujita S, Gilroy RK, Rodriguez-Davalos MI, Stevens SM, Woller SC, Alonso, D (2020). Thromboembolism-risk-based Algorithm Decreases Anticoagulation Rates and Bleeding Risk After Liver Transplantation. [Abstract]. 104(S3), S480-S481.

Video/Film/CD/Web/Podcast

  1. Stevens SM, Woller SC, Fontaine G (2019). Deep Vein Thrombosis (Update)  [Web]. London, United Kingdom: BMJ Best Practice.
  2. Stevens SM, Woller SC, Fontaine G (2019). Pulmonary Embolism [Web]. London, United Kingdom: BMJ Best Practice.
  3. Stevens SM, Woller SC, Fontaine G (2019). Anticoagulation Management Principles (Update)  [Web]. London, United Kingdom: BMJ Best Practice.

Video